Global Biologic Drugs

Biologic Drugs Comprehensive Study by Type (Vaccines, Blood and Blood Components, Allergenics, Somatic Cells, Gene Therapy, Tissues, Recombinant Therapeutic Proteins), Application (Cancer, Rheumatoid Arthritis, Diabetes, Crohn’s Disease, Multiple Sclerosis (MS), Allergic asthma, Infertility, Others) Players and Region - Global Market Outlook to 2026

Biologic Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Biologic Drugs Market Overview:
Biologic Drugs are also referred to as biopharmaceuticals or biologics. These are complex molecules manufactured in a living system such as plants, microorganisms, or animal cells. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or maybe living entities such as cells and tissues. They are produced by biotechnology methods and usually administered via injection or infusion. Since the manufacturing of biologics uses living cells, every batch of biologics has slight variations. Biologics represent the cutting-edge of biomedical research and, may be used to treat a variety of medical conditions for which no other treatments are available. Some of the players profiled in the study are Pfizer (United States), Roche Holding AG (Switzerland), Johnson & Johnson (United States), Sanofi (France), Merck & Co. (United States), Novartis (Switzerland), AbbVie Inc. (United States), Amgen (United States), Abbott Laboratories (United States) and Biogen (United States).

On the basis of geography, the market of Biologic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Growth Drivers
  • Increased Prevalence of Cancer and Diabetes Worldwide is Raising Demand for Biologics
  • Improving Reimbursement Policies Is Further Fueling Demand


Restraints
  • High Cost of Drugs Due To Complicated Manufacturing Procedures
  • Stringent Government Regulations

Opportunities
  • Rising Disposable Incomes and Improving Healthcare Facilities in Emerging Nations


Key Market Developments:



The Food and Drug Administration of the United States (FDA) has laid regulatory norms for biologics. Most biological products are regulated, or licensed for marketing via a biologics license application (BLA). To obtain licensure, the sponsor (generally the manufacturer) must demonstrate in the BLA that the biological product, and that the facility in which it is manufactured, processed, packed, or held, meet standards to assure that the product is safe, pure, and potent.

Target Audience:
Biologic Drugs Manufacturer, Biologic Drugs Raw Material Supplier, Biologic Drugs End-User, Healthcare Industry, Regulatory & Government Bodies and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Biologic Drugs market on the basis of product [Vaccines, Blood and Blood Components, Allergenics, Somatic Cells, Gene Therapy, Tissues and Recombinant Therapeutic Proteins] , application [Cancer, Rheumatoid Arthritis, Diabetes, Crohn’s Disease, Multiple Sclerosis (MS), Allergic asthma, Infertility and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Biologic Drugs market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Biologic Drugs industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Eli Lilly and Company (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Biologic Drugs market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Vaccines
  • Blood and Blood Components
  • Allergenics
  • Somatic Cells
  • Gene Therapy
  • Tissues
  • Recombinant Therapeutic Proteins
By Application
  • Cancer
  • Rheumatoid Arthritis
  • Diabetes
  • Crohn’s Disease
  • Multiple Sclerosis (MS)
  • Allergic asthma
  • Infertility
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cancer and Diabetes Worldwide is Raising Demand for Biologics
      • 3.2.2. Improving Reimbursement Policies Is Further Fueling Demand
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biologic Drugs, by Type, Application and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Biologic Drugs (Value)
      • 5.2.1. Global Biologic Drugs by: Type (Value)
        • 5.2.1.1. Vaccines
        • 5.2.1.2. Blood and Blood Components
        • 5.2.1.3. Allergenics
        • 5.2.1.4. Somatic Cells
        • 5.2.1.5. Gene Therapy
        • 5.2.1.6. Tissues
        • 5.2.1.7. Recombinant Therapeutic Proteins
      • 5.2.2. Global Biologic Drugs by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Rheumatoid Arthritis
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Crohn’s Disease
        • 5.2.2.5. Multiple Sclerosis (MS)
        • 5.2.2.6. Allergic asthma
        • 5.2.2.7. Infertility
        • 5.2.2.8. Others
      • 5.2.3. Global Biologic Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Biologic Drugs (Volume)
      • 5.3.1. Global Biologic Drugs by: Type (Volume)
        • 5.3.1.1. Vaccines
        • 5.3.1.2. Blood and Blood Components
        • 5.3.1.3. Allergenics
        • 5.3.1.4. Somatic Cells
        • 5.3.1.5. Gene Therapy
        • 5.3.1.6. Tissues
        • 5.3.1.7. Recombinant Therapeutic Proteins
      • 5.3.2. Global Biologic Drugs by: Application (Volume)
        • 5.3.2.1. Cancer
        • 5.3.2.2. Rheumatoid Arthritis
        • 5.3.2.3. Diabetes
        • 5.3.2.4. Crohn’s Disease
        • 5.3.2.5. Multiple Sclerosis (MS)
        • 5.3.2.6. Allergic asthma
        • 5.3.2.7. Infertility
        • 5.3.2.8. Others
      • 5.3.3. Global Biologic Drugs Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Biologic Drugs (Price)
      • 5.4.1. Global Biologic Drugs by: Type (Price)
  • 6. Biologic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biogen (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Biologic Drugs Sale, by Type, Application and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Biologic Drugs (Value)
      • 7.2.1. Global Biologic Drugs by: Type (Value)
        • 7.2.1.1. Vaccines
        • 7.2.1.2. Blood and Blood Components
        • 7.2.1.3. Allergenics
        • 7.2.1.4. Somatic Cells
        • 7.2.1.5. Gene Therapy
        • 7.2.1.6. Tissues
        • 7.2.1.7. Recombinant Therapeutic Proteins
      • 7.2.2. Global Biologic Drugs by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Rheumatoid Arthritis
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Crohn’s Disease
        • 7.2.2.5. Multiple Sclerosis (MS)
        • 7.2.2.6. Allergic asthma
        • 7.2.2.7. Infertility
        • 7.2.2.8. Others
      • 7.2.3. Global Biologic Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Biologic Drugs (Volume)
      • 7.3.1. Global Biologic Drugs by: Type (Volume)
        • 7.3.1.1. Vaccines
        • 7.3.1.2. Blood and Blood Components
        • 7.3.1.3. Allergenics
        • 7.3.1.4. Somatic Cells
        • 7.3.1.5. Gene Therapy
        • 7.3.1.6. Tissues
        • 7.3.1.7. Recombinant Therapeutic Proteins
      • 7.3.2. Global Biologic Drugs by: Application (Volume)
        • 7.3.2.1. Cancer
        • 7.3.2.2. Rheumatoid Arthritis
        • 7.3.2.3. Diabetes
        • 7.3.2.4. Crohn’s Disease
        • 7.3.2.5. Multiple Sclerosis (MS)
        • 7.3.2.6. Allergic asthma
        • 7.3.2.7. Infertility
        • 7.3.2.8. Others
      • 7.3.3. Global Biologic Drugs Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Biologic Drugs (Price)
      • 7.4.1. Global Biologic Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biologic Drugs: by Type(USD Million)
  • Table 2. Biologic Drugs Vaccines , by Region USD Million (2015-2020)
  • Table 3. Biologic Drugs Blood and Blood Components , by Region USD Million (2015-2020)
  • Table 4. Biologic Drugs Allergenics , by Region USD Million (2015-2020)
  • Table 5. Biologic Drugs Somatic Cells , by Region USD Million (2015-2020)
  • Table 6. Biologic Drugs Gene Therapy , by Region USD Million (2015-2020)
  • Table 7. Biologic Drugs Tissues , by Region USD Million (2015-2020)
  • Table 8. Biologic Drugs Recombinant Therapeutic Proteins , by Region USD Million (2015-2020)
  • Table 9. Biologic Drugs: by Application(USD Million)
  • Table 10. Biologic Drugs Cancer , by Region USD Million (2015-2020)
  • Table 11. Biologic Drugs Rheumatoid Arthritis , by Region USD Million (2015-2020)
  • Table 12. Biologic Drugs Diabetes , by Region USD Million (2015-2020)
  • Table 13. Biologic Drugs Crohn’s Disease , by Region USD Million (2015-2020)
  • Table 14. Biologic Drugs Multiple Sclerosis (MS) , by Region USD Million (2015-2020)
  • Table 15. Biologic Drugs Allergic asthma , by Region USD Million (2015-2020)
  • Table 16. Biologic Drugs Infertility , by Region USD Million (2015-2020)
  • Table 17. Biologic Drugs Others , by Region USD Million (2015-2020)
  • Table 18. South America Biologic Drugs, by Country USD Million (2015-2020)
  • Table 19. South America Biologic Drugs, by Type USD Million (2015-2020)
  • Table 20. South America Biologic Drugs, by Application USD Million (2015-2020)
  • Table 21. Brazil Biologic Drugs, by Type USD Million (2015-2020)
  • Table 22. Brazil Biologic Drugs, by Application USD Million (2015-2020)
  • Table 23. Argentina Biologic Drugs, by Type USD Million (2015-2020)
  • Table 24. Argentina Biologic Drugs, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Biologic Drugs, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Biologic Drugs, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Biologic Drugs, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Biologic Drugs, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Biologic Drugs, by Application USD Million (2015-2020)
  • Table 30. China Biologic Drugs, by Type USD Million (2015-2020)
  • Table 31. China Biologic Drugs, by Application USD Million (2015-2020)
  • Table 32. Japan Biologic Drugs, by Type USD Million (2015-2020)
  • Table 33. Japan Biologic Drugs, by Application USD Million (2015-2020)
  • Table 34. India Biologic Drugs, by Type USD Million (2015-2020)
  • Table 35. India Biologic Drugs, by Application USD Million (2015-2020)
  • Table 36. South Korea Biologic Drugs, by Type USD Million (2015-2020)
  • Table 37. South Korea Biologic Drugs, by Application USD Million (2015-2020)
  • Table 38. Taiwan Biologic Drugs, by Type USD Million (2015-2020)
  • Table 39. Taiwan Biologic Drugs, by Application USD Million (2015-2020)
  • Table 40. Australia Biologic Drugs, by Type USD Million (2015-2020)
  • Table 41. Australia Biologic Drugs, by Application USD Million (2015-2020)
  • Table 42. Rest of Asia-Pacific Biologic Drugs, by Type USD Million (2015-2020)
  • Table 43. Rest of Asia-Pacific Biologic Drugs, by Application USD Million (2015-2020)
  • Table 44. Europe Biologic Drugs, by Country USD Million (2015-2020)
  • Table 45. Europe Biologic Drugs, by Type USD Million (2015-2020)
  • Table 46. Europe Biologic Drugs, by Application USD Million (2015-2020)
  • Table 47. Germany Biologic Drugs, by Type USD Million (2015-2020)
  • Table 48. Germany Biologic Drugs, by Application USD Million (2015-2020)
  • Table 49. France Biologic Drugs, by Type USD Million (2015-2020)
  • Table 50. France Biologic Drugs, by Application USD Million (2015-2020)
  • Table 51. Italy Biologic Drugs, by Type USD Million (2015-2020)
  • Table 52. Italy Biologic Drugs, by Application USD Million (2015-2020)
  • Table 53. United Kingdom Biologic Drugs, by Type USD Million (2015-2020)
  • Table 54. United Kingdom Biologic Drugs, by Application USD Million (2015-2020)
  • Table 55. Netherlands Biologic Drugs, by Type USD Million (2015-2020)
  • Table 56. Netherlands Biologic Drugs, by Application USD Million (2015-2020)
  • Table 57. Rest of Europe Biologic Drugs, by Type USD Million (2015-2020)
  • Table 58. Rest of Europe Biologic Drugs, by Application USD Million (2015-2020)
  • Table 59. MEA Biologic Drugs, by Country USD Million (2015-2020)
  • Table 60. MEA Biologic Drugs, by Type USD Million (2015-2020)
  • Table 61. MEA Biologic Drugs, by Application USD Million (2015-2020)
  • Table 62. Middle East Biologic Drugs, by Type USD Million (2015-2020)
  • Table 63. Middle East Biologic Drugs, by Application USD Million (2015-2020)
  • Table 64. Africa Biologic Drugs, by Type USD Million (2015-2020)
  • Table 65. Africa Biologic Drugs, by Application USD Million (2015-2020)
  • Table 66. North America Biologic Drugs, by Country USD Million (2015-2020)
  • Table 67. North America Biologic Drugs, by Type USD Million (2015-2020)
  • Table 68. North America Biologic Drugs, by Application USD Million (2015-2020)
  • Table 69. United States Biologic Drugs, by Type USD Million (2015-2020)
  • Table 70. United States Biologic Drugs, by Application USD Million (2015-2020)
  • Table 71. Canada Biologic Drugs, by Type USD Million (2015-2020)
  • Table 72. Canada Biologic Drugs, by Application USD Million (2015-2020)
  • Table 73. Mexico Biologic Drugs, by Type USD Million (2015-2020)
  • Table 74. Mexico Biologic Drugs, by Application USD Million (2015-2020)
  • Table 75. Biologic Drugs Sales: by Type(Millilitre)
  • Table 76. Biologic Drugs Sales Vaccines , by Region Millilitre (2015-2020)
  • Table 77. Biologic Drugs Sales Blood and Blood Components , by Region Millilitre (2015-2020)
  • Table 78. Biologic Drugs Sales Allergenics , by Region Millilitre (2015-2020)
  • Table 79. Biologic Drugs Sales Somatic Cells , by Region Millilitre (2015-2020)
  • Table 80. Biologic Drugs Sales Gene Therapy , by Region Millilitre (2015-2020)
  • Table 81. Biologic Drugs Sales Tissues , by Region Millilitre (2015-2020)
  • Table 82. Biologic Drugs Sales Recombinant Therapeutic Proteins , by Region Millilitre (2015-2020)
  • Table 83. Biologic Drugs Sales: by Application(Millilitre)
  • Table 84. Biologic Drugs Sales Cancer , by Region Millilitre (2015-2020)
  • Table 85. Biologic Drugs Sales Rheumatoid Arthritis , by Region Millilitre (2015-2020)
  • Table 86. Biologic Drugs Sales Diabetes , by Region Millilitre (2015-2020)
  • Table 87. Biologic Drugs Sales Crohn’s Disease , by Region Millilitre (2015-2020)
  • Table 88. Biologic Drugs Sales Multiple Sclerosis (MS) , by Region Millilitre (2015-2020)
  • Table 89. Biologic Drugs Sales Allergic asthma , by Region Millilitre (2015-2020)
  • Table 90. Biologic Drugs Sales Infertility , by Region Millilitre (2015-2020)
  • Table 91. Biologic Drugs Sales Others , by Region Millilitre (2015-2020)
  • Table 92. South America Biologic Drugs Sales, by Country Millilitre (2015-2020)
  • Table 93. South America Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 94. South America Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 95. Brazil Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 96. Brazil Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 97. Argentina Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 98. Argentina Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 99. Rest of South America Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 100. Rest of South America Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 101. Asia Pacific Biologic Drugs Sales, by Country Millilitre (2015-2020)
  • Table 102. Asia Pacific Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 103. Asia Pacific Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 104. China Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 105. China Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 106. Japan Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 107. Japan Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 108. India Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 109. India Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 110. South Korea Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 111. South Korea Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 112. Taiwan Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 113. Taiwan Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 114. Australia Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 115. Australia Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 116. Rest of Asia-Pacific Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 117. Rest of Asia-Pacific Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 118. Europe Biologic Drugs Sales, by Country Millilitre (2015-2020)
  • Table 119. Europe Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 120. Europe Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 121. Germany Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 122. Germany Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 123. France Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 124. France Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 125. Italy Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 126. Italy Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 127. United Kingdom Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 128. United Kingdom Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 129. Netherlands Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 130. Netherlands Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 131. Rest of Europe Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 132. Rest of Europe Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 133. MEA Biologic Drugs Sales, by Country Millilitre (2015-2020)
  • Table 134. MEA Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 135. MEA Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 136. Middle East Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 137. Middle East Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 138. Africa Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 139. Africa Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 140. North America Biologic Drugs Sales, by Country Millilitre (2015-2020)
  • Table 141. North America Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 142. North America Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 143. United States Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 144. United States Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 145. Canada Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 146. Canada Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 147. Mexico Biologic Drugs Sales, by Type Millilitre (2015-2020)
  • Table 148. Mexico Biologic Drugs Sales, by Application Millilitre (2015-2020)
  • Table 149. Biologic Drugs: by Type(USD/Units)
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Biologic Drugs: by Type(USD Million)
  • Table 161. Biologic Drugs Vaccines , by Region USD Million (2021-2026)
  • Table 162. Biologic Drugs Blood and Blood Components , by Region USD Million (2021-2026)
  • Table 163. Biologic Drugs Allergenics , by Region USD Million (2021-2026)
  • Table 164. Biologic Drugs Somatic Cells , by Region USD Million (2021-2026)
  • Table 165. Biologic Drugs Gene Therapy , by Region USD Million (2021-2026)
  • Table 166. Biologic Drugs Tissues , by Region USD Million (2021-2026)
  • Table 167. Biologic Drugs Recombinant Therapeutic Proteins , by Region USD Million (2021-2026)
  • Table 168. Biologic Drugs: by Application(USD Million)
  • Table 169. Biologic Drugs Cancer , by Region USD Million (2021-2026)
  • Table 170. Biologic Drugs Rheumatoid Arthritis , by Region USD Million (2021-2026)
  • Table 171. Biologic Drugs Diabetes , by Region USD Million (2021-2026)
  • Table 172. Biologic Drugs Crohn’s Disease , by Region USD Million (2021-2026)
  • Table 173. Biologic Drugs Multiple Sclerosis (MS) , by Region USD Million (2021-2026)
  • Table 174. Biologic Drugs Allergic asthma , by Region USD Million (2021-2026)
  • Table 175. Biologic Drugs Infertility , by Region USD Million (2021-2026)
  • Table 176. Biologic Drugs Others , by Region USD Million (2021-2026)
  • Table 177. South America Biologic Drugs, by Country USD Million (2021-2026)
  • Table 178. South America Biologic Drugs, by Type USD Million (2021-2026)
  • Table 179. South America Biologic Drugs, by Application USD Million (2021-2026)
  • Table 180. Brazil Biologic Drugs, by Type USD Million (2021-2026)
  • Table 181. Brazil Biologic Drugs, by Application USD Million (2021-2026)
  • Table 182. Argentina Biologic Drugs, by Type USD Million (2021-2026)
  • Table 183. Argentina Biologic Drugs, by Application USD Million (2021-2026)
  • Table 184. Rest of South America Biologic Drugs, by Type USD Million (2021-2026)
  • Table 185. Rest of South America Biologic Drugs, by Application USD Million (2021-2026)
  • Table 186. Asia Pacific Biologic Drugs, by Country USD Million (2021-2026)
  • Table 187. Asia Pacific Biologic Drugs, by Type USD Million (2021-2026)
  • Table 188. Asia Pacific Biologic Drugs, by Application USD Million (2021-2026)
  • Table 189. China Biologic Drugs, by Type USD Million (2021-2026)
  • Table 190. China Biologic Drugs, by Application USD Million (2021-2026)
  • Table 191. Japan Biologic Drugs, by Type USD Million (2021-2026)
  • Table 192. Japan Biologic Drugs, by Application USD Million (2021-2026)
  • Table 193. India Biologic Drugs, by Type USD Million (2021-2026)
  • Table 194. India Biologic Drugs, by Application USD Million (2021-2026)
  • Table 195. South Korea Biologic Drugs, by Type USD Million (2021-2026)
  • Table 196. South Korea Biologic Drugs, by Application USD Million (2021-2026)
  • Table 197. Taiwan Biologic Drugs, by Type USD Million (2021-2026)
  • Table 198. Taiwan Biologic Drugs, by Application USD Million (2021-2026)
  • Table 199. Australia Biologic Drugs, by Type USD Million (2021-2026)
  • Table 200. Australia Biologic Drugs, by Application USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Biologic Drugs, by Type USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Biologic Drugs, by Application USD Million (2021-2026)
  • Table 203. Europe Biologic Drugs, by Country USD Million (2021-2026)
  • Table 204. Europe Biologic Drugs, by Type USD Million (2021-2026)
  • Table 205. Europe Biologic Drugs, by Application USD Million (2021-2026)
  • Table 206. Germany Biologic Drugs, by Type USD Million (2021-2026)
  • Table 207. Germany Biologic Drugs, by Application USD Million (2021-2026)
  • Table 208. France Biologic Drugs, by Type USD Million (2021-2026)
  • Table 209. France Biologic Drugs, by Application USD Million (2021-2026)
  • Table 210. Italy Biologic Drugs, by Type USD Million (2021-2026)
  • Table 211. Italy Biologic Drugs, by Application USD Million (2021-2026)
  • Table 212. United Kingdom Biologic Drugs, by Type USD Million (2021-2026)
  • Table 213. United Kingdom Biologic Drugs, by Application USD Million (2021-2026)
  • Table 214. Netherlands Biologic Drugs, by Type USD Million (2021-2026)
  • Table 215. Netherlands Biologic Drugs, by Application USD Million (2021-2026)
  • Table 216. Rest of Europe Biologic Drugs, by Type USD Million (2021-2026)
  • Table 217. Rest of Europe Biologic Drugs, by Application USD Million (2021-2026)
  • Table 218. MEA Biologic Drugs, by Country USD Million (2021-2026)
  • Table 219. MEA Biologic Drugs, by Type USD Million (2021-2026)
  • Table 220. MEA Biologic Drugs, by Application USD Million (2021-2026)
  • Table 221. Middle East Biologic Drugs, by Type USD Million (2021-2026)
  • Table 222. Middle East Biologic Drugs, by Application USD Million (2021-2026)
  • Table 223. Africa Biologic Drugs, by Type USD Million (2021-2026)
  • Table 224. Africa Biologic Drugs, by Application USD Million (2021-2026)
  • Table 225. North America Biologic Drugs, by Country USD Million (2021-2026)
  • Table 226. North America Biologic Drugs, by Type USD Million (2021-2026)
  • Table 227. North America Biologic Drugs, by Application USD Million (2021-2026)
  • Table 228. United States Biologic Drugs, by Type USD Million (2021-2026)
  • Table 229. United States Biologic Drugs, by Application USD Million (2021-2026)
  • Table 230. Canada Biologic Drugs, by Type USD Million (2021-2026)
  • Table 231. Canada Biologic Drugs, by Application USD Million (2021-2026)
  • Table 232. Mexico Biologic Drugs, by Type USD Million (2021-2026)
  • Table 233. Mexico Biologic Drugs, by Application USD Million (2021-2026)
  • Table 234. Biologic Drugs Sales: by Type(Millilitre)
  • Table 235. Biologic Drugs Sales Vaccines , by Region Millilitre (2021-2026)
  • Table 236. Biologic Drugs Sales Blood and Blood Components , by Region Millilitre (2021-2026)
  • Table 237. Biologic Drugs Sales Allergenics , by Region Millilitre (2021-2026)
  • Table 238. Biologic Drugs Sales Somatic Cells , by Region Millilitre (2021-2026)
  • Table 239. Biologic Drugs Sales Gene Therapy , by Region Millilitre (2021-2026)
  • Table 240. Biologic Drugs Sales Tissues , by Region Millilitre (2021-2026)
  • Table 241. Biologic Drugs Sales Recombinant Therapeutic Proteins , by Region Millilitre (2021-2026)
  • Table 242. Biologic Drugs Sales: by Application(Millilitre)
  • Table 243. Biologic Drugs Sales Cancer , by Region Millilitre (2021-2026)
  • Table 244. Biologic Drugs Sales Rheumatoid Arthritis , by Region Millilitre (2021-2026)
  • Table 245. Biologic Drugs Sales Diabetes , by Region Millilitre (2021-2026)
  • Table 246. Biologic Drugs Sales Crohn’s Disease , by Region Millilitre (2021-2026)
  • Table 247. Biologic Drugs Sales Multiple Sclerosis (MS) , by Region Millilitre (2021-2026)
  • Table 248. Biologic Drugs Sales Allergic asthma , by Region Millilitre (2021-2026)
  • Table 249. Biologic Drugs Sales Infertility , by Region Millilitre (2021-2026)
  • Table 250. Biologic Drugs Sales Others , by Region Millilitre (2021-2026)
  • Table 251. South America Biologic Drugs Sales, by Country Millilitre (2021-2026)
  • Table 252. South America Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 253. South America Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 254. Brazil Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 255. Brazil Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 256. Argentina Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 257. Argentina Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 258. Rest of South America Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 259. Rest of South America Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 260. Asia Pacific Biologic Drugs Sales, by Country Millilitre (2021-2026)
  • Table 261. Asia Pacific Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 262. Asia Pacific Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 263. China Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 264. China Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 265. Japan Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 266. Japan Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 267. India Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 268. India Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 269. South Korea Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 270. South Korea Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 271. Taiwan Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 272. Taiwan Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 273. Australia Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 274. Australia Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 275. Rest of Asia-Pacific Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 276. Rest of Asia-Pacific Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 277. Europe Biologic Drugs Sales, by Country Millilitre (2021-2026)
  • Table 278. Europe Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 279. Europe Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 280. Germany Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 281. Germany Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 282. France Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 283. France Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 284. Italy Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 285. Italy Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 286. United Kingdom Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 287. United Kingdom Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 288. Netherlands Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 289. Netherlands Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 290. Rest of Europe Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 291. Rest of Europe Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 292. MEA Biologic Drugs Sales, by Country Millilitre (2021-2026)
  • Table 293. MEA Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 294. MEA Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 295. Middle East Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 296. Middle East Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 297. Africa Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 298. Africa Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 299. North America Biologic Drugs Sales, by Country Millilitre (2021-2026)
  • Table 300. North America Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 301. North America Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 302. United States Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 303. United States Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 304. Canada Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 305. Canada Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 306. Mexico Biologic Drugs Sales, by Type Millilitre (2021-2026)
  • Table 307. Mexico Biologic Drugs Sales, by Application Millilitre (2021-2026)
  • Table 308. Biologic Drugs: by Type(USD/Units)
  • Table 309. Research Programs/Design for This Report
  • Table 310. Key Data Information from Secondary Sources
  • Table 311. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biologic Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Biologic Drugs: by Application USD Million (2015-2020)
  • Figure 6. South America Biologic Drugs Share (%), by Country
  • Figure 7. Asia Pacific Biologic Drugs Share (%), by Country
  • Figure 8. Europe Biologic Drugs Share (%), by Country
  • Figure 9. MEA Biologic Drugs Share (%), by Country
  • Figure 10. North America Biologic Drugs Share (%), by Country
  • Figure 11. Global Biologic Drugs: by Type Millilitre (2015-2020)
  • Figure 12. Global Biologic Drugs: by Application Millilitre (2015-2020)
  • Figure 13. South America Biologic Drugs Share (%), by Country
  • Figure 14. Asia Pacific Biologic Drugs Share (%), by Country
  • Figure 15. Europe Biologic Drugs Share (%), by Country
  • Figure 16. MEA Biologic Drugs Share (%), by Country
  • Figure 17. North America Biologic Drugs Share (%), by Country
  • Figure 18. Global Biologic Drugs: by Type USD/Units (2015-2020)
  • Figure 19. Global Biologic Drugs share by Players 2020 (%)
  • Figure 20. Global Biologic Drugs share by Players (Top 3) 2020(%)
  • Figure 21. Global Biologic Drugs share by Players (Top 5) 2020(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2020
  • Figure 25. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2020
  • Figure 31. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 33. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 35. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 38. Amgen (United States) Revenue: by Geography 2020
  • Figure 39. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 40. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 41. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 42. Biogen (United States) Revenue: by Geography 2020
  • Figure 43. Global Biologic Drugs: by Type USD Million (2021-2026)
  • Figure 44. Global Biologic Drugs: by Application USD Million (2021-2026)
  • Figure 45. South America Biologic Drugs Share (%), by Country
  • Figure 46. Asia Pacific Biologic Drugs Share (%), by Country
  • Figure 47. Europe Biologic Drugs Share (%), by Country
  • Figure 48. MEA Biologic Drugs Share (%), by Country
  • Figure 49. North America Biologic Drugs Share (%), by Country
  • Figure 50. Global Biologic Drugs: by Type Millilitre (2021-2026)
  • Figure 51. Global Biologic Drugs: by Application Millilitre (2021-2026)
  • Figure 52. South America Biologic Drugs Share (%), by Country
  • Figure 53. Asia Pacific Biologic Drugs Share (%), by Country
  • Figure 54. Europe Biologic Drugs Share (%), by Country
  • Figure 55. MEA Biologic Drugs Share (%), by Country
  • Figure 56. North America Biologic Drugs Share (%), by Country
  • Figure 57. Global Biologic Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Roche Holding AG (Switzerland)
  • Johnson & Johnson (United States)
  • Sanofi (France)
  • Merck & Co. (United States)
  • Novartis (Switzerland)
  • AbbVie Inc. (United States)
  • Amgen (United States)
  • Abbott Laboratories (United States)
  • Biogen (United States)
Additional players considered in the study are as follows:
Eli Lilly and Company (United States)
Select User Access Type

Key Highlights of Report


May 2021 243 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biologic Drugs Quantitative research analysis
Global Biologic Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Biologic Drugs Report?

Have a Query? Click Here

Other Related Reports

Cephalosporin Comprehensive Study by Type (Branded, Generics), Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Others...
$ 3750
Xylanase Comprehensive Study by Type (Feed grade, Food grade), Application (Feed and livestock, Bleaching of wood pulp, Additive (in poultry), Bakery, Agro waste treatment), End User Industry (Paper ...
$ 3450
Oligonucleotide Pool Library Comprehensive Study by Type (12K Different Oligo per Pools, 90K Different Oligo per Pools, Other), Application (Target Capture, CRISPR/Cas9 Designs, Gene Synthesis, Libra...
$ 3350
Microalgae Comprehensive Study by Type (Spirulina, Chlorella, Arthrospira, Tetraselmis, Others), Application (Food and Feed, Pharmaceuticals, Biofuels), Compounds (Pigments, Fatty acids, Anti-oxidant...
$ 3500
Pectinase Comprehensive Study by Type (Protopectinases, Polygalacturonases, Pectin Lyases, Pectinesterase), End User Industry (Food Industry, Aquaculture Industry, Winemaking Industry, Textile Indust...
$ 3350
Protein Engineering Comprehensive Study by Type (Modified Enzymes, Insulin, Monoclonal Antibodies, Coagulation Factors (Blood factors + Tissue plasminogen), Vaccines, Growth Factors (Hormones + Cytok...
$ 3750